Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 706487, 10 pages
http://dx.doi.org/10.1155/2014/706487
Research Article

New Treatment for Alzheimer’s Disease, Kamikihito, Reverses Amyloid- -Induced Progression of Tau Phosphorylation and Axonal Atrophy

1Division of Neuromedical Science, Department of Bioscience, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
2Department of Japanese Oriental Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan

Received 12 September 2013; Accepted 11 January 2014; Published 23 February 2014

Academic Editor: Toshiaki Kogure

Copyright © 2014 Hidetoshi Watari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Ministry of Health, Labour and Welfare, http://www.mhlw.go.jp/houdou_kouhou/kaiken_shiryou-/2013/-130607-01.html.
  2. WHO, “Dementia: a public health priority,” 2012.
  3. S. Gauthier and J. L. Molinuevo, “Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease,” Alzheimer's & Dementia, vol. 9, no. 3, pp. 326–331, 2013. View at Publisher · View at Google Scholar
  4. Y. Huang and L. Mucke, “Alzheimer mechanisms and therapeutic strategies,” Cell, vol. 148, no. 6, pp. 1204–1222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Mullane and M. Williams, “Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?” Biochemcal Pharmacology, vol. 85, no. 3, pp. 289–305, 2012. View at Publisher · View at Google Scholar
  6. M. Farlow, S. E. Arnold, C. H. van Dyck et al., “Safety and biomarker effects of solanezumab in patients with Alzheimer's disease,” Alzheimer's & Dementia, vol. 8, no. 4, pp. 261–271, 2012. View at Publisher · View at Google Scholar
  7. C. Tohda, R. Nakada, T. Urano, A. Okonogi, and T. Kuboyama, “Kamikihi-to (KKT) rescues axonal and synaptic degeneration associated with memory impairment in a mouse model of Alzheimer's disease, 5XFAD,” International Journal of Neuroscience, vol. 121, no. 12, pp. 641–648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Oakley, S. L. Cole, S. Logan et al., “Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation,” The Journal of Neuroscience, vol. 26, no. 40, pp. 10129–10140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. Q.-L. Ma, F. Yang, E. R. Rosario et al., “β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin,” The Journal of Neuroscience, vol. 29, no. 28, pp. 9078–9089, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Jin, N. Shepardson, T. Yang, G. Chen, D. Walsh, and D. J. Selkoe, “Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5819–5824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Ittner, T. Fath, Y. D. Ke et al., “Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 41, pp. 15997–16002, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-M. Mocanu, A. Nissen, K. Eckermann et al., “The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous tau in inducible mouse models of tauopathy,” The Journal of Neuroscience, vol. 28, no. 3, pp. 737–748, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. D. C. David, S. Hauptmann, I. Scherping et al., “Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice,” The Journal of Biological Chemistry, vol. 280, no. 25, pp. 23802–23814, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. K. P. Giese, “GSK-3: a key player in neurodegeneration and memory,” IUBMB Life, vol. 61, no. 5, pp. 516–521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. S. Park, H. J. Jung, Y. J. Kim et al., “Asp664 cleavage of amyloid precursor protein induces tau phosphorylation by decreasing protein phosphatase 2A activity,” Journal of Neurochemistry, vol. 123, no. 5, pp. 856–865, 2012. View at Publisher · View at Google Scholar
  16. P. Salcedo-Tello, A. Ortiz-Matamoros, and C. Arias, “GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration,” International Journal of Alzheimer's Disease, vol. 2011, Article ID 189728, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Onishi, H. Iwashita, Y. Uno et al., “A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease,” Journal of Neurochemistry, vol. 119, no. 6, pp. 1330–1340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Serenó, M. Coma, M. Rodríguez et al., “A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo,” Neurobiology of Disease, vol. 35, no. 3, pp. 359–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Wischik and R. Staff, “Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of tau-aggregation inhibitor therapy,” The Journal of Nutrition, Health and Aging, vol. 13, no. 4, pp. 367–369, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Fleisher, R. Raman, E. R. Siemers et al., “Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease,” Archives of Neurology, vol. 65, no. 8, pp. 1031–1038, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Rapoport, H. N. Dawson, L. I. Binder, M. P. Vitek, and A. Ferreira, “Tau is essential to β-amyloid-induced neurotoxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 9, pp. 6364–6369, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. E. D. Roberson, K. Scearce-Levie, J. J. Palop et al., “Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model,” Science, vol. 316, no. 5825, pp. 750–754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Liu, I. Grundke-Iqbal, K. Iqbal, and C.-X. Gong, “Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation,” European Journal of Neuroscience, vol. 22, no. 8, pp. 1942–1950, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M. O. Chohan, S. Khatoon, I.-G. Iqbal, and K. Iqbal, “Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine,” FEBS Letters, vol. 580, no. 16, pp. 3973–3979, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. D. Gunnarsson, L. Kilander, H. Basun, and L. Lannfelt, “Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 24, no. 4, pp. 247–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. van Eersel, Y. D. Ke, X. Liu et al., “Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 31, pp. 13888–13893, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Egashira, N. Manome, K. Kurauchi et al., “Kamikihi-to, a Kampo medicine, ameliorates impairment of spatial memory in rats,” Phytotherapy Research, vol. 21, no. 2, pp. 126–129, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Nishizawa and A. Yamashita, “Effects of Kamikihi-to, a traditional Chinese medicine, on behavioral changes induced by methyl-β-carboline-3-carboxylate in mice and rats,” Japanese Journal of Pharmacology, vol. 75, no. 4, pp. 391–397, 1997. View at Google Scholar · View at Scopus
  29. C. Tohda, N. Matsumoto, K. Zou, M. R. Meselhy, and K. Komatsu, “Aβ(25–35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, a metabolite of protopanaxadiol-type saponins,” Neuropsychopharmacology, vol. 29, no. 5, pp. 860–868, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Naito and C. Tohda, “Characterization of anti-neurodegenerative effects of Polygala tenuifolia in Aβ(25–35)-treated cortical neurons,” Biological and Pharmaceutical Bulletin, vol. 29, no. 9, pp. 1892–1896, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Cavalli, M. L. Bolognesi, A. Mìnarini et al., “Multi-target-directed ligands to combat neurodegenerative diseases,” Journal of Medicinal Chemistry, vol. 51, no. 3, pp. 347–372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Capurro, P. Busquet, J. P. Lopes et al., “Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease,” PLoS ONE, vol. 8, no. 2, Article ID e56870, 2013. View at Publisher · View at Google Scholar
  33. C. Huang, C. Zheng, Y. Li, Y. Wang, A. Lu, and L. Yang, “Systems pharmacology in drug discovery and therapeutic insight for herbal medicines,” Briefings in Bioinformatics, 2013. View at Publisher · View at Google Scholar